Trump outlines steep tariffs on generic drugs

President Donald Trump has unveiled a new tariff schedule for generic drugs imported into the United States, laying out a multi‑year escalation in duties. In a social‑media announcement, he said all imported generic pharmaceuticals will remain tariff‑free for two years starting August 1, 2026. After that period, the tariffs are set to rise sharply under a fixed timetable.

Under the plan, generic drug imports will face a 100% tariff for one year beginning August 1, 2028. After that one‑year phase, the tariff rate is slated to increase to 200%. The announcement establishes a clear sequence of rising import costs for generics if manufacturers do not alter their production footprint.

Trump described the measure as designed “to RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them.” He characterized the escalating duties as a penalty rather than an immediate blanket increase, pointing to the initial two‑year period of zero tariffs as a grace window.

The stated objective is to push generic drugmakers to move production onshore by making it more costly to keep manufacturing abroad once the higher tariff rates begin. The structured timeline is presented as giving companies advance notice and time to adjust supply chains and investment plans before the tariffs climb.

The new tariff plan focuses on a major segment of the U.S. pharmaceutical market. Multiple reports note that more than 90% of medicines sold in the United States are generics, citing data from the U.S. Food and Drug Administration. This underscores the breadth of products potentially affected by the announced changes.

Because generic medicines account for the vast majority of U.S. prescriptions, any shift in the cost structure of imported generics could have far‑reaching implications for the drug supply chain. The planned tariff levels and timing are likely to be closely watched by manufacturers and buyers throughout the market.

The decision to maintain a 0% tariff until August 1, 2028 creates a defined transition period before the sharp increase to a 100% levy and the subsequent move to 200%. This structure effectively separates the policy into a near‑term status quo phase and a later period of significant trade restrictions on imported generics.

With the schedule now publicly set out, generic drugmakers face a clear timetable for potential cost increases on U.S. imports. The combination of a brief continuation of zero tariffs and a rapid escalation afterward outlines a policy approach that couples immediate stability with substantial future changes to trade conditions for generic pharmaceuticals.